Brief: AB Science Gets Positive Recommendation For masitinib In COVID-19 Study

AB Science SA

14/09/2022 17:25

Sept 14 (Reuters) - AB SCIENCE SA  ABS.PA :
    * POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING
BOARD
TO CONTINUE THE PHASE 2 STUDY EVALUATING THE ANTIVIRAL ACTIVITY
OF MASITINIB IN COVID-19
    * STUDY IS TARGETING SAME POPULATION AS REGISTERED ANTIVIRAL
TREATMENTS, NAMELY PAXLOVID (PFIZER) AND MOLNUPIRAVIR (MERCK)

Source text for Eikon:  ID:nGNXbBGrRj 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))